June 9, 2022 03:23 PM EDT
R&D

#BIO22 sur­vey: The E100 as­sess the Nas­daq win­ter that is freez­ing out biotech. But hir­ing re­mains a top pri­or­i­ty

John Carroll

Editor & Founder

There’s no deny­ing the na­ture of the sea change bio­phar­ma is un­der­go­ing to­day as the IPO win­dow re­mains large­ly slammed shut. And the mes­sage has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times